FEMY · Femasys Inc
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, substantial doubt exists about the Company's ability to continue as a going concern for at least one year from the issuance of these financial statements.”View the 10-Q filed May 8, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $2.38M | $2.29M | $1.63M | $1.07M | $1.21M | $1.18M | |
| $913.74K | $872.4K | $544.9K | $380.07K | $441.94K | $370.38K | |
| $705.87K | — | — | — | $764.28K | $809.31K | |
| — | — | — | — | 63.36% | 68.6% | |
| $5.92M | $7.58M | $8.22M | $7.21M | $5.81M | $4.08M | |
| $4.85M | $4.44M | $4.03M | $650.13K | $558.85K | $208.74K | |
| $6.71M | $6.65M | $6.33M | $6.86M | $5.43M | $4.26M | |
| — | $46.18K | $20.14K | $3294 | $21.8K | $39.98K | |
| $339.45K | $342.03K | $297.32K | $483.48K | $561.23K | $591.07K | |
| $17.81M | $19.01M | $18.87M | $15.2M | $12.36M | $9.15M | |
| -$16.35M | -$17.59M | -$17.79M | -$14.51M | -$11.6M | -$8.34M | |
| — | -766.95% | -1091.75% | -1353.43% | -961.71% | -706.7% | |
| -$16.01M | -$17.25M | -$17.49M | -$14.02M | -$11.04M | -$7.75M | |
| $1.61M | $1.89M | $1.6M | $165.39K | $13.46K | $19.23K | |
| $132.56K | $101.76K | $582.35K | — | — | — | |
| $4.47M | -$1.04M | -$1.02M | $265.63K | $212.39K | $802.96K | |
| -$11.88M | -$18.63M | -$18.81M | -$14.24M | -$11.39M | -$7.53M | |
| $5485 | $1297 | $9602 | $4338 | $6300 | $4000 | |
| -$11.88M | -$18.63M | -$18.82M | -$14.25M | -$11.39M | -$7.54M | |
| — | -812.27% | -1155.03% | -1329.06% | -944.62% | -638.97% | |
| — | — | — | — | — | -$7.54M | |
| USD/shares | — | -$9.40 | -$17.00 | -$18.60 | -$19.20 | -$22.40 |
| USD/shares | — | -$9.40 | -$17.00 | -$18.60 | -$19.20 | -$22.40 |
| shares | — | 1.98M | 1.11M | 769.22K | 590.75K | 335.6K |
| shares | — | 1.98M | 1.11M | 769.22K | 590.75K | 335.6K |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2024: $290.71K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 21 similar-size Medical Instruments & Supplies companies (of 50 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Business Segment | $2,293,313 | $1,629,108 | $1,071,970 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| United States | $1,393,555 | $1,073,508 | $1,013,925 | $1,090,359 | $1,005,612 | $900,751 |
| Non Us | $899,758 | $555,600 | $58,045 | $115,859 | $174,077 | $137,167 |
By Product & Service (USD)
| Component | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| FemVue | $1,071,970 | $1,206,218 | $1,179,689 | $1,037,918 |